JP2015514227A - 結核バイオマーカーおよびその使用 - Google Patents

結核バイオマーカーおよびその使用 Download PDF

Info

Publication number
JP2015514227A
JP2015514227A JP2015505956A JP2015505956A JP2015514227A JP 2015514227 A JP2015514227 A JP 2015514227A JP 2015505956 A JP2015505956 A JP 2015505956A JP 2015505956 A JP2015505956 A JP 2015505956A JP 2015514227 A JP2015514227 A JP 2015514227A
Authority
JP
Japan
Prior art keywords
biomarker
individual
biomarkers
biological sample
tuberculosis infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015505956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514227A5 (enExample
Inventor
オクスナー，ウルス
スターリング，デヴィッド・ジー
ジャンジク，ネボジャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Inc
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of JP2015514227A publication Critical patent/JP2015514227A/ja
Publication of JP2015514227A5 publication Critical patent/JP2015514227A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015505956A 2012-04-13 2013-04-12 結核バイオマーカーおよびその使用 Pending JP2015514227A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623732P 2012-04-13 2012-04-13
US61/623,732 2012-04-13
PCT/US2013/036447 WO2013155460A1 (en) 2012-04-13 2013-04-12 Tuberculosis biomarkers and uses thereof

Publications (2)

Publication Number Publication Date
JP2015514227A true JP2015514227A (ja) 2015-05-18
JP2015514227A5 JP2015514227A5 (enExample) 2016-06-09

Family

ID=49328218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015505956A Pending JP2015514227A (ja) 2012-04-13 2013-04-12 結核バイオマーカーおよびその使用

Country Status (6)

Country Link
US (3) US20140155411A1 (enExample)
EP (1) EP2836608A4 (enExample)
JP (1) JP2015514227A (enExample)
CA (1) CA2867481A1 (enExample)
HK (1) HK1205764A1 (enExample)
WO (1) WO2013155460A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019510206A (ja) * 2016-02-09 2019-04-11 メディカル リサーチ カウンシルＭｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｕｎｃｉｌ Ｔｂバイオマーカー
WO2020162441A1 (ja) * 2019-02-04 2020-08-13 国立大学法人大阪大学 肉芽腫性疾患バイオマーカー
JP2022550825A (ja) * 2019-09-30 2022-12-05 ユニバーシティ・オブ・ケープ・タウン 尿サンプル中において結核の診断を行なうための方法
JP2024531418A (ja) * 2021-08-20 2024-08-29 ジェネスペクター エス．アール．オー． 感染症の重症度を予測する方法、ならびにその方法の実施および感染症の治療の観察に使用するバイオマーカー

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1205764A1 (en) 2012-04-13 2015-12-24 Somalogic, Inc. Tuberculosis biomarkers and uses thereof
WO2015164616A1 (en) * 2014-04-24 2015-10-29 Somalogic, Inc. Biomarkers for detection of tuberculosis
WO2016182967A1 (en) * 2015-05-08 2016-11-17 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
GB201519872D0 (en) * 2015-11-11 2015-12-23 Univ Cape Town And Ct For Infectious Disease Res Biomarkers for prospective determination of risk for development of active tuberculosis
WO2017179008A1 (en) * 2016-04-15 2017-10-19 Stellenbosch University Host biomarkers for immunodiagnosis and monitoring of tuberculosis disease
US10607228B1 (en) * 2016-08-24 2020-03-31 Jpmorgan Chase Bank, N.A. Dynamic rule strategy and fraud detection system and method
US20200058369A1 (en) * 2016-11-02 2020-02-20 Biois Co., Ltd. Quantitative Cluster Analysis Method Of Target Protein By Using Next-Generation Sequencing And Use Thereof
WO2018106481A1 (en) * 2016-12-09 2018-06-14 Basil Leaf Technologies, Llc Computer-implemented methods, systems, and computer-readable media for diagnosing a condition
JP6812789B2 (ja) * 2016-12-28 2021-01-13 富士通株式会社 情報処理装置、情報処理プログラム、および情報処理方法
WO2019202448A1 (en) * 2018-04-16 2019-10-24 University Of Cape Town A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis
CN112034176B (zh) * 2020-07-09 2022-08-30 中国工程物理研究院材料研究所 Cntn1作为长期低剂量电离辐射暴露诊断的分子标记物的用途
US20220026417A1 (en) * 2020-07-21 2022-01-27 Industry-University Cooperation Foundation, Catholic University of Pusan Method of simultaneously diagnosing active tuberculosis and latent tuberculosis infection using human whole blood sample-derived biomarker
CN112481369A (zh) * 2020-12-03 2021-03-12 中国医学科学院病原生物学研究所 Msrb1作为结核病诊断分子标识的用途
US11676726B2 (en) * 2021-06-22 2023-06-13 David Haase Apparatus and method for generating a treatment plan for salutogenesis
WO2023021262A1 (en) * 2021-08-17 2023-02-23 Scotland's Rural College Methods of determining animal phenotypes
CN114250310B (zh) * 2021-11-15 2023-12-08 四川大学华西医院 用于检测结核病的dna甲基化标志物、诊断模型、甲基化探针及试剂盒
CN115466797A (zh) * 2022-06-06 2022-12-13 四川大学华西第二医院 用于检测rs4770965和rs9507713的试剂在制备结核筛查试剂盒中的用途
WO2024091936A1 (en) * 2022-10-24 2024-05-02 Inflammatix, Inc. A fluidic device and methods for characterization of an infection or other condition
EP4467662A1 (en) 2023-05-26 2024-11-27 Forschungszentrum Borstel, Leibniz Lungenzentrum Method for predicting the time point of culture conversion in individuals
CN119689002B (zh) * 2025-02-25 2025-06-06 山东大学 用于预测胚胎反复种植失败的生物标志物组合、试剂盒及其应用和联合药物及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007024631A (ja) * 2005-07-14 2007-02-01 Human Science Shinko Zaidan 同位体標識法
WO2007103770A2 (en) * 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
JP2008545960A (ja) * 2005-05-23 2008-12-18 セント ジョージズ エンタープライゼズ リミテッド 結核の診断
WO2009028880A2 (en) * 2007-08-30 2009-03-05 Snu R & Db Foundation Biomarker composition for detecting diabetic retinopathy and diagnostic kit therefor
JP2010506144A (ja) * 2006-08-15 2010-02-25 プロメテウス ラボラトリーズ インコーポレイテッド 過敏性腸症候群診断方法
WO2011066008A2 (en) * 2009-11-30 2011-06-03 Baylor Research Institute Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
US20110196614A1 (en) * 2008-06-25 2011-08-11 Baylor Research Institute Blood transcriptional signature of mycobacterium tuberculosis infection
CN103065065A (zh) * 2012-11-18 2013-04-24 浙江大学 一种活动性肺结核蛋白表达差异质谱模型及构建方法
JP2013523117A (ja) * 2010-03-31 2013-06-17 フイルメニツヒ ソシエテ アノニム フレーバーを含んでなる中実カプセルの製造

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143506A (en) * 1998-08-13 2000-11-07 The Research Foundation Of State Of Ny Diagnostic method for detection of periodontitis or peri-implantitis
AU2003241055A1 (en) * 2002-06-20 2004-01-06 Glaxo Group Limited Surrogate markers for the determination of the disease status of an individual infected by mycobacterium tuberculosis
US20060009378A1 (en) * 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
KR20060015646A (ko) * 2003-06-13 2006-02-17 유니버시티 오브 피츠버그 면역, 혈액 및 염증성 질환의 모니터링 방법
DE602006020467D1 (de) * 2005-09-26 2011-04-14 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
AT505727B1 (de) * 2007-09-04 2009-06-15 Univ Innsbruck Verfahren zur diagnose des metabolischen syndroms
EP2430451B1 (en) * 2009-05-14 2014-08-13 The Chancellors, Masters and Scholars of the University of Oxford Clinical diagnosis of hepatic fibrosis / cirrhosis using low abundant human plasma protein biomarkers
EP2558586B1 (en) * 2010-04-12 2016-10-12 Somalogic, Inc. APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
HK1205764A1 (en) 2012-04-13 2015-12-24 Somalogic, Inc. Tuberculosis biomarkers and uses thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545960A (ja) * 2005-05-23 2008-12-18 セント ジョージズ エンタープライゼズ リミテッド 結核の診断
JP2007024631A (ja) * 2005-07-14 2007-02-01 Human Science Shinko Zaidan 同位体標識法
WO2007103770A2 (en) * 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
JP2010506144A (ja) * 2006-08-15 2010-02-25 プロメテウス ラボラトリーズ インコーポレイテッド 過敏性腸症候群診断方法
WO2009028880A2 (en) * 2007-08-30 2009-03-05 Snu R & Db Foundation Biomarker composition for detecting diabetic retinopathy and diagnostic kit therefor
US20110196614A1 (en) * 2008-06-25 2011-08-11 Baylor Research Institute Blood transcriptional signature of mycobacterium tuberculosis infection
JP2011526152A (ja) * 2008-06-25 2011-10-06 ベイラー リサーチ インスティテュート マイコバクテリウム・ツベルクローシス感染症の血液転写サイン
WO2011066008A2 (en) * 2009-11-30 2011-06-03 Baylor Research Institute Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
JP2013523117A (ja) * 2010-03-31 2013-06-17 フイルメニツヒ ソシエテ アノニム フレーバーを含んでなる中実カプセルの製造
CN103065065A (zh) * 2012-11-18 2013-04-24 浙江大学 一种活动性肺结核蛋白表达差异质谱模型及构建方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALMEIDA MARIA LUIZA DORIA: "alpha1-acid glycoprotein and alpha1-antitrypsin as early markers of treatment response in patients r", TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, vol. 103, no. 6, JPN6017010862, June 2009 (2009-06-01), pages 575 - 580, ISSN: 0003527206 *
CRITICAL CARE, vol. 17, no. 1, JPN6017048848, 2013, pages 27, ISSN: 0003706403 *
DJOBA SIAWAYA J F: "Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 156, no. 1, JPN6017010864, April 2009 (2009-04-01), pages 69 - 77, ISSN: 0003527207 *
J BIOL CHEM, vol. 277, no. 38, JPN6017048846, 20 September 2002 (2002-09-20), pages 34708 - 34716, ISSN: 0003706401 *
PANCREAS, vol. 19, no. 4, JPN6017048849, November 1999 (1999-11-01), pages 325 - 334, ISSN: 0003873876 *
RESPIRATORY MEDICAL RESEARCH, vol. 3, no. 3, JPN6017048847, 2015, pages 45 - 47, ISSN: 0003706402 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019510206A (ja) * 2016-02-09 2019-04-11 メディカル リサーチ カウンシルＭｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｕｎｃｉｌ Ｔｂバイオマーカー
WO2020162441A1 (ja) * 2019-02-04 2020-08-13 国立大学法人大阪大学 肉芽腫性疾患バイオマーカー
JP2022550825A (ja) * 2019-09-30 2022-12-05 ユニバーシティ・オブ・ケープ・タウン 尿サンプル中において結核の診断を行なうための方法
JP7607950B2 (ja) 2019-09-30 2025-01-06 ユニバーシティ・オブ・ケープ・タウン 尿サンプル中において結核の診断を行なうための方法
JP2024531418A (ja) * 2021-08-20 2024-08-29 ジェネスペクター エス．アール．オー． 感染症の重症度を予測する方法、ならびにその方法の実施および感染症の治療の観察に使用するバイオマーカー

Also Published As

Publication number Publication date
EP2836608A4 (en) 2016-02-24
US20180128839A1 (en) 2018-05-10
US20140155411A1 (en) 2014-06-05
CA2867481A1 (en) 2013-10-17
WO2013155460A1 (en) 2013-10-17
EP2836608A1 (en) 2015-02-18
HK1205764A1 (en) 2015-12-24
US10408847B2 (en) 2019-09-10
US20160109462A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
US10408847B2 (en) Tuberculosis biomarkers and uses thereof
CN102209968B (zh) 肺癌生物标记蛋白的捕获剂在制备试剂盒中的用途
CN102985819B (zh) 肺癌生物标记及其用途
JP5931874B2 (ja) 膵癌バイオマーカーおよびその使用
KR102248900B1 (ko) 심혈관 위험 사건 예측 및 그것의 용도
CN103890586A (zh) 肺癌生物标记及其用途
CA2843756A1 (en) Renal cell carcinoma biomarkers and uses thereof
WO2015164616A1 (en) Biomarkers for detection of tuberculosis
JP2025118715A (ja) 心血管リスク／イベントの予測及びその使用
US20180356419A1 (en) Biomarkers for detection of tuberculosis risk
WO2023278502A1 (en) Renal health determination and uses thereof
US20240255524A1 (en) Renal Insufficiency Prediction and Uses Thereof
HK40073398A (en) Cardiovascular risk event prediction and uses thereof
JP2025186325A (ja) 耐糖能異常障害を決定する方法
JP2023546563A (ja) 心血管イベントリスクの予測
HK1236619A1 (en) Cardiovascular risk event prediction and uses thereof
HK1229003B (zh) 胰腺癌生物标记及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180905